IGF-1R inhibition in the Treatment of RAS/RAF Mutant Advanced Colorectal Cancer: A Randomised Phase II study comparing FOLFIRI plus Dalotuzumab to FOLFIRI alone in patients with KRAS or BRAF mutant previously untreated advanced colorectal cancer (I-TRAC)

Trial Profile

IGF-1R inhibition in the Treatment of RAS/RAF Mutant Advanced Colorectal Cancer: A Randomised Phase II study comparing FOLFIRI plus Dalotuzumab to FOLFIRI alone in patients with KRAS or BRAF mutant previously untreated advanced colorectal cancer (I-TRAC)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2016

At a glance

  • Drugs Dalotuzumab; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms I-TRAC
  • Most Recent Events

    • 05 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top